J. Grinfeld's Profile

Role	Title	Level	Year	L/R
🐜	Effect of mutation order on myeloproliferative neoplasms. 21 auth. Christina A. Ortmann, David G. Kent, J. Nangalia, Y. Silber, D. Wedge, J. Grinfeld, E. J. Baxter, Charlie E Massie, E. Papaemmanuil, S. Menon, ... A. Godfrey, D. Dimitropoulou, P. Guglielmelli, B. Bellosillo, C. Besses, K. Döhner, C. Harrison, G. Vassiliou, A. Vannucchi, Peter J. Campbell, Anthony R. Green	8	2015	8 🐜
🦁	Classification and Personalized Prognosis in Myeloproliferative Neoplasms 27 auth. J. Grinfeld, J. Nangalia, J. Baxter, D. Wedge, Nicos Angelopoulos, R. Cantrill, A. Godfrey, E. Papaemmanuil, G. Gundem, C. Maclean, J. Cook, Laura O'Neil, S. O’Meara, J. Teague, A. Butler, ... C. Massie, N. Williams, Francesca L. Nice, C. Andersen, H. Hasselbalch, P. Guglielmelli, M. McMullin, A. Vannucchi, C. Harrison, M. Gerstung, A. Green, P. Campbell	8	2018	8 🦁
🐜	DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype 12 auth. J. Nangalia, Francesca L. Nice, D. Wedge, A. Godfrey, J. Grinfeld, C. Thakker, ... C. Massie, J. Baxter, David Sewell, Y. Silber, P. Campbell, A. Green	6	2015	6 🐜
🦁	Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms J. Grinfeld, J. Nangalia, A. Green	6	2017	6 🦁
🐜	Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. 18 auth. Juan Li, Daniel Prins, H. J. Park, J. Grinfeld, C. Gonzalez-Arias, S. Loughran, O. Dovey, T. Klampfl, Cavan Bennett, Tina L. Hamilton, ... Dean C. Pask, R. Sneade, Matthew Williams, J. Aungier, C. Ghevaert, G. Vassiliou, D. Kent, A. Green	6	2018	6 🐜
🐜	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features 15 auth. A. Godfrey, P. Campbell, C. Maclean, G. Buck, J. Cook, J. Temple, B. Wilkins, K. Wheatley, J. Nangalia, J. Grinfeld, ... M. McMullin, C. Forsyth, J. Kiladjian, A. Green, C. Harrison	5	2018	5 🐜
🐜	Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia 18 auth. N. Øbro, J. Grinfeld, M. Belmonte, Melissa Irvine, Mairi S. Shepherd, T. N. Rao, A. Karow, L. M. Riedel, Oliva B. Harris, E. Baxter, ... J. Nangalia, A. Godfrey, C. Harrison, Juan Li, R. Skoda, P. Campbell, A. Green, D. Kent	5	2020	5 🐜
🦁	A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia 16 auth. J. Grinfeld, G. Gerrard, M. Alikian, J. Alonso‐Dominguez, Sakuntala Ale, M. Valgañón, Georgios Nteliopoulos, D. White, D. Marin, C. Hedgley, ... S. O'brien, R. Clark, J. Goldman, D. Milojkovic, J. Apperley, L. Foroni	5	2013	5 🦁
🐬	Pathogenesis of Myeloproliferative Disorders. J. Nangalia, J. Grinfeld, A. Green	5	2016	5 🐬
🦁	After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. J. Grinfeld, A. Godfrey	4	2017	4 🦁